Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis

Page, Kathleen R.; Sifakis, Frangiscos; de, Ruben Montes; Cronin, Wendy A.; Doherty, Meg; Federline, Lynn; Bur, Sarah; Walsh, Thomas J.; Karney, Walter W.; Milman, James; Baruch, Nancy G.; Adelakun, Akintoye; Dorman, Susan E.

doi:10.1001/archinte.166.17.1863

Cited by 164 publications

(117 citation statements)

References 16 publications

(11 reference statements)

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…More frequent monitoring may be indicated in high-risk patients, particularly older patients and those with potential for significant drug-drug interactions. There are some data to suggest that hepatotoxicity may be less frequent with a shorter duration of the rifampicin regimen, a potentially important consideration for patients awaiting liver transplantation [86]. The optimal length of LTBI treatment has not been studied in this population.…”

Section: Prevention Of Tb In Transplant Recipientsmentioning

confidence: 99%

The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement

Bumbăcea

Arend

Eyüboğlu³

et al. 2012

Eur Respir J

218

253

View full text Add to dashboard Cite

Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell transplantation. The identification of candidates for preventive chemotherapy is an effective intervention to protect transplant recipients with latent infection with Mycobacterium tuberculosis from progressing to active disease. The best available proxy for diagnosing latent infection with M. tuberculosis is the identification of an adaptive immune response by the tuberculin skin test or an interferon-c based ex vivo assay. Risk assessment in transplant recipients for the development of TB depends on, among other factors, the locally expected underlying prevalence of infection with M. tuberculosis in the target population. In areas of high prevalence, preventive chemotherapy for all transplant recipients may be justified without immunodiagnostic testing while in areas of medium and low prevalence, preventive chemotherapy should only be offered to candidates with positive M. tuberculosis-specific immune responses. The diagnosis of TB in transplant recipients can be challenging. Treatment of TB is often difficult due to substantial interactions between anti-TB drugs and immunosuppressive medications. This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking. KEYWORDS: Guideline, management, Mycobacterium tuberculosis, transplantation, tuberculosis T uberculosis (TB) is caused by the pathogenic species of the Mycobacterium tuberculosis complex. Only a minority of individuals who develop an adaptive immune response following infection with M. tuberculosis will ever develop TB, with the actual risk depending on the extent to which the host immune system provides a successful or inadequate response [1,2]. Therefore, individuals with impaired immune response, such as solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, are more prone to develop TB than immunocompetent persons. TB in transplant recipients is more frequent compared to the general population (estimates from the last decades state 20-74 times as frequent in SOT [3,4] and twice as frequent in HSCT [5]), and more often fatal (up to 31% in SOT [6] and up to 50% in HSCT recipients [7]), thus adding effectiveness to interventions for its prevention, even in the face of difficulties, with treatment related to adverse drug events and drug-drug interactions. Active TB in transplant recipients can result from latent infection with M. tuberculosis (LTBI) in the transplant candidate or in the donor tissue, or from de novo post-transplant infection. These various scenarios prompt for targeted pre-transplant screening of both recipient and, if possible, donors to allow focused management of recipients selected for preventive intervention in the pre-and/or posttransplant period. The term ''preventive chemotherapy'' is used to denote treatmen...

show abstract

Section: Prevention Of Tb In Transplant Recipientsmentioning

confidence: 99%

The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement

Bumbăcea

Arend

Eyüboğlu³

et al. 2012

Eur Respir J

218

253

View full text Add to dashboard Cite

show abstract

“…4 A four-month regimen with RMP seemed to be associated with better completion rates, ranging from 72% to 91%. [10][11][12] The aim of this study was to evaluate the proportion of adult patients who started LTBI treatment and completed it within 12 months of first prescription.…”

mentioning

confidence: 99%

Completion Rates of Treatment for Latent Tuberculosis Infection in Quebec, Canada From 2006 to 2010

Rivest

Street

Allard

2013

Can J Public Health

View full text Add to dashboard Cite

“…Un traitement plus court prévoit la prise quotidienne de rifampicine (RMP) pendant quatre mois. Ce schéma s'est révélé aussi sûr que l'INH9, en plus de présenter un meilleur taux d'observance; son efficacité reste toutefois à établir (10,11). À cette fin, un essai randomisé contrôlé multicentrique multinational comparant l'efficacité de la rifampicine à celle de l'INH9 devrait bientôt être terminé (12).…”

Section: Traitement De L'infection Tuberculeuse Latenteunclassified

Un schéma thérapeutique plus court qui s'annonce prometteur pour le traitement de l'infection tuberculeuse latente chez les Canadiens à risque

Pease¹,

Amaratunga²,

Alvarez³

2017

RMTC

View full text Add to dashboard Cite

Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis

Cited by 164 publications

References 16 publications

The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement

The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement

Completion Rates of Treatment for Latent Tuberculosis Infection in Quebec, Canada From 2006 to 2010

Un schéma thérapeutique plus court qui s'annonce prometteur pour le traitement de l'infection tuberculeuse latente chez les Canadiens à risque

Contact Info

Product

Resources

About